---
title: "Advanced Breast Cancer (ABC) Treatment | Kisqali®"
description: "Discover the proven efficacy and powerful consistency of KISQALI® for HR+/HER2- advanced breast cancer (ABC) in both postmenopausal and premenopausal patients, with demonstrated survival and quality of life benefits."
canonical_url: "https://www.kisqali.com/advanced-breast-cancer"
meta:
  "og:description": "Discover the proven efficacy and powerful consistency of KISQALI® for HR+/HER2- advanced breast cancer (ABC) in both postmenopausal and premenopausal patients, with demonstrated survival and quality of life benefits."
  "og:title": "Advanced Breast Cancer (ABC) Treatment"
---

## **Proven efficacy**

![Fictional portrait of a smilling  black postmenopausal woman representing the MONALEESA-2 breast cancer study design.](https://www.kisqali.com/img/advanced-breast-cancer/monaleesa-2-study-woman-portrait.webp)

MONALEESA-2

**KISQALI + AI in 1L postmenopausal patients**

visibility

![Fictional portrait of a smilling Middle Eastern  postmenopausal woman representing the MONALEESA-3 advanced breast cancer clinical trial.](https://www.kisqali.com/img/advanced-breast-cancer/monaleesa-3-study-woman-portrait.webp)

MONALEESA-3

**KISQALI + fulvestrant in 1L/2L postmenopausal patients**

visibility

![Fictional portrait of a smiling asian premenopausal woman used for MONALEESA-7 breast cancer study design.](https://www.kisqali.com/img/advanced-breast-cancer/monaleesa-7-study-woman-portrait.webp)

MONALEESA-7

**KISQALI + ET in 1L premenopausal patients**

visibility

## **Give more of your patients **<br>**news worth sharing**

### **In HR+/HER2- ABC, KISQALI + ET:**

![Fictional patient and caregiver smiling while talking about KISQALI® treatment for advanced breast cancer.](https://www.kisqali.com/img/advanced-breast-cancer/abc-patient-conversation.webp)

[<h3>check\_circleOverall survival (OS)</h3>The only CDK4/6i with statistically significant 1L m0S benefit across three phase III trials<sup>†(1-4)</sup>](https://www.kisqali.com/advanced-breast-cancer/efficacy/efficacy-across-trials) [<h3>check\_circleQuality of life (QOL)</h3>Consistently preserves QOL across phase III trials and achieved a time to deterioration (TTD) ≥10% across trials<sup>(5-8)</sup>](https://www.kisqali.com/advanced-breast-cancer/health-related-quality-of-life) [<h3>check\_circleSafety profile</h3>A well-established safety profile consistent across a broad range of patients<sup>(9-12)</sup>](https://www.kisqali.com/advanced-breast-cancer/safety-data/safety-profile)

## **For Healthcare Professionals Outside the US**

KISQALI is indicated in the EU for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.  
  
 KISQALI in combination with an aromatase inhibitor is indicated in the EU for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

![City river view encouraging healthcare professionals to access country-specific NovartisPro information.](https://www.kisqali.com/img/advanced-breast-cancer/mobile/local-hcp-portal.webp)

**Visit your local HCP portal for further country specific information**

This website is intended for Health Care Professionals (HCPs) outside the US and Switzerland. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information. By clicking continue you are confirming that you are an HCP.

## Sitemap

See the full [sitemap](/sitemap.md) for all pages.